|1.||Osterhaus, A D: 5 articles (12/2001 - 08/2000)|
|2.||Jennings, R: 4 articles (02/2003 - 04/2000)|
|3.||Hess, John F: 3 articles (03/2010 - 12/2004)|
|4.||Angelos, John A: 3 articles (03/2010 - 12/2004)|
|5.||Mowat, Allan McI: 3 articles (06/2006 - 05/2002)|
|6.||Lycke, Nils Y: 2 articles (09/2011 - 01/2007)|
|7.||Kisser, Ulrich: 2 articles (07/2011 - 02/2011)|
|8.||Dauer, Marc: 2 articles (07/2011 - 02/2011)|
|9.||Heckelsmiller, Klaus: 2 articles (07/2011 - 02/2011)|
|10.||Endres, Stefan: 2 articles (07/2011 - 02/2011)|
04/14/2000 - "Almost complete protection against HSV-2 challenge was afforded by the HSV-2 ISCOM preparation, while partial protection against challenge infection was afforded by the HSV-2 NISV 30 vaccine formulation. "
04/01/2000 - "Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs."
12/12/2001 - "Here we have tested a PhHV-1 based ISCOM vaccine for its protective efficacy against FHV infection in cats. "
12/01/2000 - "In addition, when T cells from immunized mice were adoptively transferred into syngeneic naive animals and challenged intravaginally with Chlamydia, recipients of IM immunization of MOMP-ISCOMs cleared their infection within 1 week and were resistant to reinfection. "
01/01/1995 - "The findings indicate that the ISCOM delivery system can be used for immunisation by the oral route, although in mice, under the conditions used, this strategy compares unfavourably with the intramuscular route in terms of both local and systemic immune responses and protection against homologous challenge virus infection."
|2.||Human Influenza (Influenza)
05/01/1998 - "Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes."
05/01/2008 - "The aim of this study was to evaluate EIV-specific immune responses after intra-muscular vaccination with an ISCOM-EIV vaccine (EQUIP F) containing both equine influenza H7N7 (A/eq/Newmarket/77) and H3N8 (A/eq/Borlänge/91 and A/eq/Kentucky/98) strains. "
01/15/2012 - "ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse."
12/15/2005 - "The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses."
12/02/2004 - "Protective responses generated by vaccination with an immuno-stimulating complex (ISCOM)-based vaccine for equine influenza (EQUIP F), containing a new 'American lineage' H3N8 virus, were studied. "
03/29/1984 - "Iscoms of PI-3 and measles viruses also stimulate the formation of antibody to the fusion (F) protein, which is considered to be poorly immunogenic. "
08/01/1998 - "The data indicate that the further exploration of the potential of iscom based measles vaccines should be encouraged."
03/29/1984 - "Iscoms have been prepared with membrane proteins of para-influenza-3 (PI-3), measles and rabies viruses, and their immunizing potency tested in animals. "
05/01/1998 - "The liposomal technology for preparing the immunostimulating complex (ISCOM) helped obtain a complex measles preparation whose antigens are represented by the structural proteins of measles virus in the bilayer phosphate-lipid membrane. "
10/01/1988 - "Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs."
|4.||Rubella (German Measles)
12/01/1988 - "Neutralizing response of rabbits to an experimental rubella subunit vaccine made from immunostimulating complexes."
12/01/1988 - "Rubella ISCOMs were as efficient as the live vaccine in inducing neutralizing and hemagglutination inhibiting antibodies, suggesting the possibility of developing an ISCOMs subunit vaccine."
12/01/1988 - "Rubella ISCOMs were tested for their capacity to induce neutralizing and hemagglutination-inhibiting antibodies, in comparison with a commercial live attenuated vaccine. "
06/01/1987 - "Rubella hemagglutinin immuno-stimulating complexes preparations were also better visualized and their morphology conserved after direct ultracentrifugation on the specimen grids. "
08/15/2000 - "To test this concept, the immunogenicity and protective efficacy of two standard (Moraten and trivalent measles, mumps, rubella) and four experimental (two recombinant ALVAC, one ISCOM subunit and live attenuated Edmonston-Zagreb) MV vaccines were evaluated in naïve cotton rats, and cotton rats with passively acquired MV-specific neutralizing serum antibodies. "
04/20/2005 - "Two groups of 10 BALB/c mice were immunised twice, on days 0 and 28 with iscoms containing either the recombinant NcSRS2 (NcSRS2 iscoms) or similar iscoms with NcSRS2 substituted by an unrelated recombinant malaria peptide (M5) as a control (M5 iscoms). "
02/01/1996 - "Much of the work on ISCOMs has remained in the area of vaccine research where there is still an urgent need for improved adjuvants to help combat important diseases such as AIDS, malaria and influenza. "
|4.||Membrane Proteins (Integral Membrane Proteins)
|6.||Proteins (Proteins, Gene)
|7.||Membrane Glycoproteins (Membrane Glycoprotein)
|4.||Drug Therapy (Chemotherapy)